p53 and cell cycle independent dysregulation of autophagy in chronic lymphocytic leukaemia

British Journal of Cancer

Volumn 109, Issue 9, 2013, Pages 2434-2444

  Groves, M J ^a   Johnson, C E ^a   James, J ^a   Prescott, A R ^a   Cunningham, J ^b   Haydock, S ^b   Pepper, C ^c   Fegan, C ^c   Pirrie, L ^d   Westwood, N J ^d   Coates, P J ^a   Ganley, I G ^a   Tauro, S ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^d Fife   (United Kingdom)

Author keywords

apoptosis; autophagy; CLL; p53; tenovin 6

Indexed keywords

ANTINEOPLASTIC AGENT; BAFILOMYCIN A1; BORTEZOMIB; CASPASE 3; CELL PROTEIN; CPG OLIGODEOXYNUCLEOTIDE; FLUDARABINE; INTERLEUKIN 2; PROTEIN P53; PROTEIN P62; TENOVIN 6; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG;

ACETYLATION; ADULT; AGED; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL ACTIVATION; CELL CULTURE; CELL DEATH; CELL ULTRASTRUCTURE; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; WESTERN BLOTTING;

EID: 84887022065     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.601     Document Type: Article

References (39)

1. Audrito V, Vaisitti T, Rossi D, Gottardi D, D'Arena G, Laurenti L, Gaidano G, Malavasi F, Deaglio S (2011) Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res 71: 4473-4483.
2. Barth S, Glick D, Macleod KF (2010) Autophagy: Assays and artifacts. J Pathol 221: 117-124.
3. Bjørkøy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, Stenmark H, Johansen T (2005) p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 171: 603-614.
4. Calissano C, Damle RN, Hayes G, Murphy EJ, Hellerstein MK, Moreno C, Sison C, Kaufman MS, Kolitz JE, Allen SL, Rai KR, Chiorazzi N (2009) In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood 114: 4832-4842.
5. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 370: 230-239.
6. Cea M, Soncini D, Fruscione F, Raffaghello L, Garuti A, Emionite L, Moran E, Magnone M, Zoppoli G, Reverberi D, Caffa I, Salis A, Cagnetta A, Bergamaschi M, Casciaro S, Pierri I, Damonte G, Ansaldi F, Gobbi M, Pistoia V, Ballestrero A, Patrone F, Bruzzone S, Nencioni A (2011) Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. PLoS One 6: E22739.
7. Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, Patel P, Bronson R, Appella E, Alt FW, Chua KF (2003) Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA 100: 10794-10799.
8. Dayal S, Sparks A, Jacob J, Allende-Vega N, Lane DP, Saville MK (2009) Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. J Biol Chem 284: 5030-5041.
9. Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, Wagner H, Peschel C (2000) Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 95: 999-1006.
10. Fuchs EJ, McKenna KA, Bedi A (1997) p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32beta. Cancer Res 57: 2550-2554.
11. Fujisawa A, Kambe N, Saito M, Nishikomori R, Tanizaki H, Kanazawa N, Adachi S, Heike T, Sagara J, Suda T, Nakahata T, Miyachi Y (2007) Disease-Associated mutations in CIAS1 induce cathepsin B-dependent rapid cell death of human THP-1 monocytic cells. Blood 109: 2903-2911.
12. García-Martínez JM, Moran J, Clarke RG, Gray A, Cosulich SC, Chresta CM, Alessi DR (2009) Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 421: 29-42.
13. Groves MJ, Maccallum SF, Boylan MT, Haydock S, Cunningham J, Gelly K, Gowans D, Kerr R, Coates PJ, Tauro S (2012) Heterogeneity of p53-pathway Protein Expression in Chemosensitive Chronic Lymphocytic Leukemia: A Pilot Study. J Cancer 3: 354-361.
14. Hussain SR, Lucas DM, Johnson AJ, Lin TS, Bakaletz AP, Dang VX, Viatchenko-Karpinski S, Ruppert AS, Byrd JC, Kuppusamy P, Crouser ED, Grever MR (2008) Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood 111: 3190-3199.
15. Kenzelmann Broz D, Spano Mello S, Bieging KT, Jiang D, Dusek RL, Brady CA, Sidow A, Attardi LD (2013) Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses. Genes Dev 27: 1016-1031.
16. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Bánhegyi G, Bartholomew CR, Bassham DC, Bast Jr. RC, Batoko H, Bay BH, Beau I, Béchet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, (2012) Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8: 445-544.
17. Knights CD, Catania J, Di Giovanni S, Muratoglu S, Perez R, Swartzbeck A, Quong AA, Zhang X, Beerman T, Pestell RG, Avantaggiati ML (2006) Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol 173: 533-544.
18. Korolchuk VI, Mansilla A, Menzies FM, Rubinsztein DC (2009) Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol Cell 33: 517-527.
19. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, Thompson A, Mathers J, Holland SJ, Stark MJ, Pass G, Woods J, Lane DP, Westwood NJ (2008) Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13: 454-463.
20. Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T, Holyoake TL, Chen W, Bhatia R (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21: 266-281.
21. Lin K, Adamson J, Johnson GG, Carter A, Oates M, Wade R, Richards S, Gonzalez D, Matutes E, Dearden C, Oscier DG, Catovsky D, Pettitt AR (2012) Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: Blockade at the level of p21 is associated with short response duration. Clin Cancer Res 18: 4191-4200.
22. Lin TT, Hewamana S, Ward R, Taylor H, Payne T, Pratt G, Baird D, Fegan C, Pepper C (2008) Highly purified CD38 sub-populations show no evidence of preferential clonal evolution despite having increased proliferative activity when compared with CD38 sub-populations derived from the same chronic lymphocytic leukaemia patient. Br J Haematol 142: 595-605.
23. MacCallum SF, Groves MJ, James J, Murray K, Appleyard V, Prescott AR, Drbal AA, Nicolaou A, Cunningham J, Haydock S, Ganley IG, Westwood NJ, Coates PJ, Lain S, Tauro S (2013) Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6. Sci Rep 3: 1275.
24. McCarthy AR, Pirrie L, Hollick JJ, Ronseaux S, Campbell J, Higgins M, Staples OD, Tran F, Slawin AM, Lain S, Westwood NJ (2012) Synthesis and biological characterisation of sirtuin inhibitors based on the tenovins. Bioorg Med Chem 20: 1779-1793.
25. McCarthy AR, Sachweh MC, Higgins M, Campbell J, Drummond CJ, van Leeuwen IM, Pirrie L, Ladds MJ, Westwood NJ, Laín S (2013) Tenovin-D3, a novel small-molecule inhibitor of Sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent manner. Mol Cancer Ther 12: 352-360.
26. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, Murphy EJ, Koduru P, Ferrarini M, Zupo S, Cutrona G, Damle RN, Wasil T, Rai KR, Hellerstein MK, Chiorazzi N (2005) In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 115: 755-764.
27. Mimnaugh EG, Chen HY, Davie JR, Celis JE, Neckers L (1997) Rapid deubiquitination of nucleosomal histones in human tumor cells caused byproteasome inhibitors and stress response inducers: Effects on replication, transcription, translation, and the cellular stress response. Biochemistry 36: 14418-14429.
28. Mohr J, Helfrich H, Fuge M, Eldering E, Bühler A, Winkler D, Volden M, Kater AP, Mertens D, Te Raa D, Döhner H, Stilgenbauer S, Zenz T (2011) DNA damage-induced transcriptional program in CLL: Biological and diagnostic implications for functional p53 testing. Blood 117: 1622-1632.
29. Napoli M, Flores ER (2013) The family that eats together stays together: New p53 family transcriptional targets in autophagy. Genes Dev 27: 971-974.
30. Natoni A, Murillo LS, Kliszczak AE, Catherwood MA, Montagnoli A, Samali A, O'Dwyer M, Santocanale C (2011) Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells. Mol Cancer Ther 10: 1624-1634.
31. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T (2001) p53 dysfunction in B-cell chronic lymphocytic leukemia: Inactivation of ATM as an alternative to TP53 mutation. Blood 98: 814-822.
32. Pirrie L, McCarthy AR, Major LL, Morkūnait.e V, Zubrien.e A, Matulis D, Lain S, Lebl T, Westwood NJ (2012) Discovery and validation of SIRT2 inhibitors based on tenovin-6: Use of a 1H-NMR method to assess deacetylase activity. Molecules 17: 12206-122024.
33. Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC, Mitchell JB, Marti GE, Fowler DH, Wilson WH, Staudt LM (2004) Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 104: 1428-1434.
34. Sunami Y, Araki M, Hironaka Y, Morishita S, Kobayashi M, Liew EL, Edahiro Y, Tsutsui M, Ohsaka A, Komatsu N (2013) Inhibition of the NAD-dependent protein deacetylase SIRT2 induces granulocytic differentiation in human leukemia cells. PLoS One 8: E57633.
35. Taatjes DJ, Sobel BE, Budd RC (2008) Morphological and cytochemical determination of cell death by apoptosis. Histochem Cell Biol 129: 33-43.
36. Tauro S, Hepburn MD, Peddie CM, Bowen DT, Pippard MJ (2002) Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes. Leukemia 16: 785-790.
37. Yuan H, Wang Z, Li L, Zhang H, Modi H, Horne D, Bhatia R, Chen W (2012) Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 119: 1904-1914.
38. Zembruski NC, Stache V, Haefeli WE, Weiss J (2012) 7-Aminoactinomycin D for apoptosis staining in flow cytometry. Anal Biochem 429: 79-81.
39. Zenz T, Kröber A, Scherer K, Häbe S, Bühler A, Benner A, Denzel T, Winkler D, Edelmann J, Schwänen C, Döhner H, Stilgenbauer S (2008) Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-Term follow-up. Blood 112: 3322-3329.